Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Phillips 66 Laying Off Staff At Refineries, Terminals, Office

-Reuters
byBenzinga Newsdesk
October 26, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

-Reuters

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Ionis and Astrazeneca’s Eplontersen Demonstrated a Statistically Significant and Clinically Meaningful Change From Baseline for Co-primary and Secondary Endpoints at 35 Weeks vs External Placebo Group

By Charles Gross
September 7, 4:50 AM
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today presented positive results from a planned 35-week interim analysis of the Phase 3 NEURO-TTRansform study of Ionis and AstraZeneca's eplontersen in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).

AZN